Company Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.
It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands.
In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.
Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin.
The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1849 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,000 |
| CEO | Albert Bourla |
Contact Details
Address: 66 Hudson Boulevard East New York, New York 10001-2192 United States | |
| Phone | 212 733 2323 |
| Website | pfizer.com |
Stock Details
| Ticker Symbol | PFE |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000078003 |
| CUSIP Number | 717081103 |
| ISIN Number | US7170811035 |
| Employer ID | 13-5315170 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board and Chief Executive Officer |
| David M. Denton | Executive Vice President and Chief Financial Officer |
| Dr. Chris Boshoff FMedSci, M.D., Ph.D. | Chief Scientific Officer and President of Research and Development |
| Aamir Malik | Executive Vice President and Chief U.S. Commercial Officer |
| Jennifer B. Damico | Senior Vice President, Controller and Principal Accounting Officer |
| Lidia L. Fonseca | Executive Vice President and Chief Digital and Technology Officer |
| Francesca M. DeMartino | Chief Investor Relations Officer |
| Douglas M. Lankler | Executive Vice President and Chief Legal Officer |
| Payal Sahni Becher | Chief People Experience Officer and Executive Vice President |
| Dr. Michael S. Vincent M.D., Ph.D. | Senior Vice President and Chief Scientific Officer of Inflammation and Immunology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Feb 3, 2026 | 8-K | Current Report |
| Dec 16, 2025 | 8-K | Current Report |
| Nov 21, 2025 | 8-K | Current Report |
| Nov 20, 2025 | 424B5 | Filing |
| Nov 19, 2025 | FWP | Free Writing Prospectus |
| Nov 18, 2025 | 424B3 | Prospectus |
| Nov 13, 2025 | 13F-HR | Quarterly report filed by institutional managers, holdings |
| Nov 13, 2025 | 8-K | Current Report |